L-type Ca2+ channel desensitization by F- reduces PhE-induced increase in [Ca2+]i but not stress

Am J Physiol. 1992 Mar;262(3 Pt 1):C621-7. doi: 10.1152/ajpcell.1992.262.3.C621.

Abstract

F- (10 mM sodium fluoride plus deferoxamine to chelate contaminating aluminum) causes arterial contractions primarily by activating L-type Ca2+ channels. Results from the present study indicate that, although F(-)-induced contractions could be completely relaxed by washing out the F- with fresh buffer, a long-lasting effect of F- pretreatment was to produce L-type Ca2+ channel desensitization. Pretreatment of arteries for 4 h with F- (followed by washout of F-) resulted in much reduced increases in stress and [Ca2+]i produced by the subsequent addition of 110 mM KCl, such that steady-state values were, respectively, only 9 and 15% of the control values. However, a 4-h F- pretreatment caused a reduction only in the rate of stress development, but not the steady-state level of stress, produced by maximum concentrations of receptor agonists. In tissues that were pretreated with F- and then stimulated with the alpha-adrenoceptor agonist, phenylephrine, steady-state stress was still 104% of the control value, while the increase in [Ca2+]i was only 10% of the control value. F- is known to inhibit protein phosphatases, and similar reductions in the ability of KCl to produce contractions and increase [Ca2+]i were seen after pretreatment with the protein phosphatase inhibitor, okadaic acid. These data suggest that L-type Ca2+ channel desensitization by F- pretreatment was caused by increased protein phosphorylation. In addition, they suggest that much of the contribution made by L-type Ca2+ channels to increase [Ca2+]i during receptor stimulation may not be necessary for the maintenance of maximum stress at steady state.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology
  • Animals
  • Calcium / metabolism*
  • Calcium Channels / drug effects
  • Calcium Channels / physiology*
  • Deferoxamine / pharmacology
  • Dinoprost / pharmacology
  • Female
  • Femoral Artery / physiology
  • Fluorides / pharmacology*
  • In Vitro Techniques
  • Male
  • Muscle Contraction / drug effects
  • Muscle Contraction / physiology*
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology*
  • Phenylephrine / pharmacology*
  • Potassium Chloride / pharmacology
  • Rabbits
  • Stress, Mechanical
  • Time Factors

Substances

  • Calcium Channels
  • Phenylephrine
  • Potassium Chloride
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
  • Dinoprost
  • Deferoxamine
  • Fluorides
  • Calcium